We review this week’s ASX news, from MNS and CPH getting caught up in ASIC probes to CBA shares tanking on their latest quarterly.
Biotech Stocks: Investing in Cutting-Edge Healthcare Innovations
Imugene Share Price Up on Agreement with Merck and Pfizer (ASX:IMU)
The Imugene [ASX:IMU] share price is up 6% following a supply agreement update. Imugene, the biotech stock, gained 600% over the last 12 months.
MSB Share Price Up — Trial Drug Helps Against Heart Attacks (ASX:MSB)
Up-and-coming biotech player Mesoblast [ASX:MSB] is on the up today. The regenerative medicine company announced some promising results from a Phase III drug trial from data that was shared at the American Heart Association’s annual ‘Scientific Sessions’, an exhibition of the latest findings and insights into all things heart health related.
‘2020’s Most Important IPO’ Sets the Stage for a New Biotech Boom
It was an opinion piece discussing the recent listing (at the time) of Compass Pathways PLC [NASDAQ:CMPS]. A biotech stock with a very distinct twist…
a2 Milk Share Price Sinks 11% on New Strategy (ASX:A2M)
‘Unprecedented change’ in the China infant formula market over the last 12 months led a2 Milk to alter its growth strategy, setting a medium-term goal of hitting NZ$2 billion in sales. a2 Milk Company [ASX:A2M] share price is currently trading for $6.09 a share, down 11%.
Oneview Shares Rise 7% as It Signs a Key Five-Year Deal (ASX:ONE)
Tiny medtech stock Oneview Healthcare PLC [ASX:ONE] is on the up today. The ONE share price currently trading 6.98% higher at time of writing, paring back earlier gains of as much as 20.9% today.
